HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo’s Rx-To-OTC Contraceptive Pill Switch Unanimously Rejected By German Committee

Executive Summary

All nine present voting members of Germany's Expert Committee for Prescription rejected Perrigo's application to switch its progestogen-only contraceptive pill (desogestrel 75μg) from Rx to OTC status. 

You may also be interested in...



Perrigo Delivering Opill Sales Within A Month, Launches ‘Energize’ Efficiency Project Immediately

Perrigo says 2024 results will be slowed by investment in companywide efficiency project including staff reductions. After Opill’s expected launch by late March, sales will be dilutive to earnings for the first year partly due to investments in the brand, primarily at retailers and online in Q2.

Pressure On Opill Price From Lawmakers, Health Advocates, Not From Marketplace Competition

Pressure from members of Congress and public and reproductive health advocacy groups will continue for making Opill’s price affordable to consumers from all income levels, but competition won’t affect the price for three years.

First US OTC Oral Contraceptive, Opill Marks Start Of Perrigo's Women’s Health ‘Mega-Brand’

“We do want to be a mega brand offering solutions across the women's sexual health journey. From the moment she enters into that category all the way through to post menopause, including fertility, we will develop out a mega brand,” says CEO Patrick Lockwood-Taylor.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel